---
title: "Butterfly's chip ships inside Mendaera's robot while insiders sold $31.95 million"
description: "Mendaera's Focalist robot became the first Butterfly Embedded product to reach market on 1 October 2026, the licensing thesis's first commercial test. Insiders sold $31.95 million of BFLY in the three months before it arrived."
publisher: "The Inference"
section: "Health"
published: 2026-10-03T07:21:37.728Z
modified: 2026-10-03T07:21:37.728Z
canonical: https://theinference.org/article/butterfly-s-chip-ships-inside-mendaera-s-robot-while-insiders-sold-31-95-million
language: en
keywords: "Butterfly Network, Insider Selling, Medical Robotics, Mendaera, Ultrasound"
---

# Butterfly's chip ships inside Mendaera's robot while insiders sold $31.95 million

> Mendaera's Focalist robot became the first Butterfly Embedded product to reach market on 1 October 2026, the licensing thesis's first commercial test. Insiders sold $31.95 million of BFLY in the three months before it arrived.

Mendaera's FDA-cleared Focalist robot, a handheld system for guiding needles in vascular access, nerve blocks and organ access, went commercially available with a customized [Butterfly](https://theinference.org/markets/companies/butterfly-network) iQ3 probe on 1 October [1]. Butterfly [calls Mendaera the first Butterfly Embedded partner to commercialize](https://www.businesswire.com/news/home/20261001065092/en/Mendaeras-Focalist-System-Now-Compatible-with-Butterflys-Ultrasound-on-Chip-Technology), which makes this week the first time the licensing thesis has a product on a shelf [1]. No financial terms were disclosed.

The rest of the pipeline sits earlier. Merge Labs, launched in January with $252 million from investors including [OpenAI](https://theinference.org/markets/companies/openai), Bain Capital and Gabe Newell and with [Sam Altman](https://theinference.org/markets/people/sam-altman) on its founding team, is building brain-computer interfaces on the chip [2]. Its multi-year licence pays Butterfly upfronts, milestones and technology-access fees; royalties are only "expected" [2]. The [Midjourney](https://theinference.org/markets/companies/midjourney) Medical full-body imaging build has not shipped [3].

Embedded already books revenue, [$5.7 million in the first quarter, up 147%](https://www.msn.com/en-us/news/other/butterfly-projects-q2-revenue-of-27m-31m-while-reaffirming-2026-revenue-of-117m-121m/ar-AA227U6P), driven primarily by Midjourney [4]. That is development money. The royalties the street is underwriting start with a robot that holds needles.

## The ledger beside the launch

[Insiders sold 4,708,246 shares for $31,950,688 in the three months to early October](https://www.defenseworld.net/2026/10/01/evercore-upgrades-butterfly-network-nysebfly-to-strong-buy.html) [5]. Director Jonathan Rothberg cut his stake 95.67%, selling 1,195,857 shares at $6.60 under a pre-arranged 10b5-1 plan, and another insider's sale covered tax withholding [5]. One director swam the other way: [Louise Phanstiel bought 115,200 shares at $8.68 on 14 August](https://www.themarketsdaily.com/2026/09/29/butterfly-network-nysebfly-shares-gap-up-should-you-buy.html), $999,936 in total [6]. Plan sales and tax sales are mechanical. The direction is still one-way.

*Chart: **$31.95 million out, $1.0 million in** Bar chart of insider transactions in Butterfly Network shares: $31.95 million of total insider sales, $7.89 million of them by Jonathan Rothberg, against a single $1.0 million purchase by Louise Phanstiel*

*Value of insider transactions in Butterfly Network shares in the three months to early October, in USD millions. Total sales of 4,708,246 shares ($31.95 million) include director Jonathan Rothberg's 1,195,857 shares at $6.60; director Louise Phanstiel's 14 August purchase of 115,200 shares at $8.68 is the only buy. MarketBeat data in the cited reports. [5][6]*

## The street pays for the chip, not the royalties

Q2 revenue of $32.61 million beat the $29.16 million consensus and cleared the top of management's own $27 million to $31 million guide, with gross margin up to 71.4% from 63.7% and the quarterly adjusted EBITDA loss narrowed to $1.4 million from $6.2 million [5][4][3]. The full year still carries a guided $19 million to $23 million adjusted EBITDA loss against $124.7 million of June cash, at a $2.38 billion market cap [3][5][7].

*Chart: **Ten quarters of growth, and the first licensed product only now ships** Line chart of Butterfly Network quarterly revenue from Q1 2024 to Q2 2026, rising from $17.66M to $32.61M*

*Quarterly revenue in USD millions as reported in Butterfly Network's SEC filings, Q1 2024 through Q2 2026. The Embedded licensing business had no product in market until October 2026. [9]*

[Needham's 22 September initiation](https://blockonomi.com/butterfly-network-bfly-stock-surges-22-following-needhams-bullish-initiation/) drove [a 22% single-day move](https://theinference.org/article/cdc-director-files-to-sell-her-entire-butterfly-stake-one-day-after-the-22-pop) to $9.93 [3]. [Evercore](https://theinference.org/markets/companies/evercore) followed on 29 September with $15 against an $8.54 consensus; TD Cowen and Needham sit at $10, and Weiss Ratings still carries a "sell (d-)" from 3 August [6][5]. The stock gapped from a $9.15 close to a $9.69 open on 29 September and last traded at $9.54, inside a one-year range of $1.87 to $10.05 [6][5].

*Chart: **Evercore's $15 stands alone above a consensus that trails the tape** Bar chart of price targets: Evercore $15, Needham $10, TD Cowen $10, above the 29 September last trade of $9.54 and the $8.54 consensus*

*Analyst price targets and consensus in USD per share alongside the 29 September last trade, from MarketBeat data in the cited reports. Targets are opinions, marked as estimates. [5][6]*

## The counter and the tell

Institutions lean in: [33 hedge funds held the stock in the second quarter against 26 a quarter earlier](https://finance.yahoo.com/technology/ai/articles/sam-altman-backed-merge-labs-033132473.html), and [BlackRock](https://theinference.org/markets/companies/blackrock) added about 17.9% to its position [8]. The short side is sizeable too: 32.18 million shares, about 15% of the float, were sold short at the 14 August settlement [8]. One columnist's line on the unshipped half of the story, "[R&D burn dressed up as a platform](https://eventph.com/business/butterflys-22-surge-the-chip-is-real-the-platform-still-isnt/)", names the standing risk: GE, Philips and Siemens own the installed bases [7]. Both companies demo at ACEP26 in Chicago, 5 to 7 October [1].

The tell is the first disclosed per-unit royalty from a partner's shipping product. The margins prove the chip. The register has yet to prove the business.

## Takeaway

The licensing thesis has its first product on a market and the chip's margins are proven; what is not proven is the per-unit royalty, and insiders did not wait for it, selling $31.95 million of BFLY in the three months before launch.

## Sources

1. [Business Wire, Mendaera's Focalist System Now Compatible with Butterfly's Ultrasound-on-Chip Technology, 1 October 2026](https://www.businesswire.com/news/home/20261001065092/en/Mendaeras-Focalist-System-Now-Compatible-with-Butterflys-Ultrasound-on-Chip-Technology)
2. [Business Wire via Morningstar, Merge Labs and Butterfly Network Partner to Advance Ultrasound-Based Brain-Computer Interfaces, 1 September 2026](https://www.morningstar.com/news/business-wire/20260901999280/merge-labs-and-butterfly-network-partner-to-advance-ultrasound-based-brain-computer-interfaces)
3. [Blockonomi, Butterfly Network (BFLY) Stock Surges 22% Following Needham's Bullish Initiation, 23 September 2026](https://blockonomi.com/butterfly-network-bfly-stock-surges-22-following-needhams-bullish-initiation/)
4. [Seeking Alpha via MSN, Butterfly projects Q2 revenue of $27M-$31M while reaffirming 2026 revenue of $117M-$121M (Q1 2026 earnings call insights), 30 April 2026](https://www.msn.com/en-us/news/other/butterfly-projects-q2-revenue-of-27m-31m-while-reaffirming-2026-revenue-of-117m-121m/ar-AA227U6P)
5. [Defense World (MarketBeat data), Evercore Upgrades Butterfly Network (NYSE:BFLY) to Strong-Buy, 1 October 2026](https://www.defenseworld.net/2026/10/01/evercore-upgrades-butterfly-network-nysebfly-to-strong-buy.html)
6. [The Markets Daily (MarketBeat data), Butterfly Network (NYSE:BFLY) Shares Gap Up - Should You Buy?, 29 September 2026](https://www.themarketsdaily.com/2026/09/29/butterfly-network-nysebfly-shares-gap-up-should-you-buy.html)
7. [EVENT PHILIPPINES (SeaPRewire), Butterfly's 22% Surge: The Chip Is Real, The Platform Still Isn't, September 2026](https://eventph.com/business/butterflys-22-surge-the-chip-is-real-the-platform-still-isnt/)
8. [Yahoo Finance / Insider Monkey, Sam Altman-Backed Merge Labs Picked Butterfly's Chips for Brain Interfaces. Is This the Breakout BFLY Needed?, 2 September 2026](https://finance.yahoo.com/technology/ai/articles/sam-altman-backed-merge-labs-033132473.html)
9. [Sharadar quarterly fundamentals, from Butterfly Network's SEC filings, retrieved 2 October 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001804176)


---

Butterfly's chip ships inside Mendaera's robot while insiders sold $31.95 million — The Inference. Canonical: https://theinference.org/article/butterfly-s-chip-ships-inside-mendaera-s-robot-while-insiders-sold-31-95-million
